DBA/2 Mouse as an Animal Model for Anti-influenza Drug Efficacy Evaluation
Jin Il Kim, Sehee Park, Sangmoo Lee, Ilseob Lee, Jun Heo, Min-Woong Hwang, Joon-Yong Bae, Donghwan Kim, Seok-Il Jang, Mee Sook Park, and Man-Seong Park*
Department of Microbiology, Center for Medical Science Research, College of Medicine, Hallym University, Chuncheon 200-702, Republic of Korea
Journal of Microbiology, 51(6),866–871, 2013,
adaptation, animal model, antiviral, DBA/2 mouse,influenza virus
Influenza viruses are seasonally recurring human pathogens.
Vaccines and antiviral drugs are available for influenza.
However, the viruses, which often change themselves via
antigenic drift and shift, demand constant efforts to update
vaccine antigens every year and develop new agents with
broad-spectrum antiviral efficacy. An animal model is critical
for such efforts. While most human influenza viruses are
unable to kill BALB/c mice, some strains have been shown
to kill DBA/2 mice without prior adaptation. Therefore, in
this study, we explored the feasibility of employing DBA/2
mice as a model in the development of anti-influenza drugs.
Unlike the BALB/c strain, DBA/2 mice were highly susceptible
and could be killed with a relatively low titer (50%
DBA/2 lethal dose = 102.83 plaque-forming units) of the A/
Korea/01/2009 virus (2009 pandemic H1N1 virus). When
treated with a neuraminidase inhibitor, oseltamivir phosphate,
infected DBA/2 mice survived until 14 days postinfection.
The reduced morbidity of the infected DBA/2
mice was also consistent with the oseltamivir treatment.
Taking these data into consideration, we propose that the
DBA/2 mouse is an excellent animal model to evaluate antiviral
efficacy against influenza infection and can be further
utilized for combination therapies or bioactivity models of
existing and newly developed anti-influenza drugs.